AAIPharma Strengthens Global Clinical Development Services Unit with the Addition of Andreas Dreps Ph.D. and Ralf Wolter Ph.D.

DATELINE (November 10, 2008) – AAIPharma, a global provider of drug development services, today announced the appointment of Andreas Dreps, Ph.D., as Senior Vice President, Global Clinical Development Services. In addition, the company also announced that Ralf Wolter, Ph.D., has joined as Vice President Clinical Operations – Europe reporting to Dr. Dreps.

“We are very fortunate to add Andreas to the leadership team of the company,” said Ludo Reynders Ph.D., CEO of AAI Pharma. “His vast drug development experience and track record, especially in the Clinical Oncology area, will be invaluable in the further development of our global clinical development business unit. As we organize our business around the customer, Andreas’ scientific understanding and business acumen will provide great value to the customers and project teams we serve.”

Dr. Reynders continued: “The addition of Dr. Wolter to Andreas’ team augments our strong foothold in Europe and his experience enhances our ability to perform large-scale global trials in key therapeutic areas.”

Dr. Dreps brings to AAIPharma more than 15 years of drug development experience including, most recently, leading the oncology therapeutic area for ICON, a large, global CRO. His prior experience includes a series of progressively responsible positions with leading pharmaceutical companies including, Merck KGaA, Rhone Poulenc Rorer/Aventis, and Bristol Myers-Squibb. He received his undergraduate degree in Biology after studies in Cologne, Bochum, and Munich, Germany and he obtained his Ph.D. following research at the Max-Plank Institute and
Stanford University. He completed a post-doctoral fellowship at Sugen Inc. in California.

Dr. Wolter possesses over 12 years of clinical research experience, including early clinical development, trial management, project management, training and business development. After 10 years at a leading, global CRO where he managed large full-service trials, Dr. Wolter more recently served as Vice President of Clinical Development for Apogenix, a German biotech company focused on oncology. Dr. Wolter received his M.Sc. and Ph.D. in biology from
Johann Wolfgang Goethe University in Frankfurt and completed post-doctoral fellowships at both Goethe University and Gutenberg University. His extensive therapeutic experience includes, oncology, cardiovascular and infectious disease.

About AAIPharma:
AAIPharma Inc. is a global drug development services company. We assist the pharmaceutical, biotechnology, and medical device industries in the pharmaceutical development, early clinical development and late-stage clinical development of their product portfolios. AAIPharma’s service offerings include: analytical services, product development services, drug delivery technologies, contract manufacturing (solids and parenterals), clinical services (Phase I-IV), clinical packaging and distribution and bioanalytical services.

For more information on the Company, please visit AAIPharma's website at www.aaipharma.com.

Contact: Barry Johnson: Barry.Johnson@aaipharma.com